Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome
-Designation provides regulatory and development incentives in Japan, including up to 10 years of market exclusivity upon approval-
-Designation provides regulatory and development incentives in Japan, including up to 10 years of market exclusivity upon approval-
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.